WuXi AppTec Co., Ltd.

Core Business

WuXi AppTec is the world's largest CRDMO (Contract Research, Development and Manufacturing Organization), providing integrated services across small molecules, biologics, and CGT. Its TIDES business (oligonucleotides and peptides) has become the cornerstone of gene therapy API supply, with 2025 revenue of RMB 45.46 billion ($6.35 billion) and TIDES segment growth of 96% year-over-year to RMB 11.37 billion. The company's TIDES manufacturing capacity reached 100,000 liters of solid-phase peptide synthesis capacity in 2025.

Global Presence

Headquartered in Shanghai, WuXi AppTec operates major facilities across China (Shanghai, Suzhou, Changzhou, Taixing, Nanjing), the US, Singapore, and Europe. The company employs approximately 39,000 people globally with an unfulfilled order backlog of RMB 580 billion, ensuring multi-year revenue visibility and customer commitment.

Key Strengths

WuXi AppTec's unparalleled manufacturing scale in TIDES (100,000L+ total reaction volume) and its end-to-end CRDMO platform create an unmatched competitive position. The company's ability to support clients from drug discovery through commercial manufacturing, combined with its dominant position in oligonucleotide supply, makes it an essential partner in the global gene therapy ecosystem. Its massive backlog provides exceptional revenue predictability.

VerityRank Score

WuXi AppTec achieves a VerityRank Score of 88/100, reflecting its dominant TIDES manufacturing capacity, extraordinary growth trajectory, and essential position in the global gene therapy oligonucleotide supply chain.

WuXi AppTec is the world's largest contract research, development and manufacturing organization, providing integrated services across small molecules, biologics, and cell and gene therapies. Its TIDES oligonucleotides and peptides business, with 100,000+ liters of solid-phase synthesis capacity, grew 96% year-over-year to RMB 11.37 billion in 2025. The company operates major manufacturing facilities across China, the US, Singapore, and Europe, employing 39,000 people with an RMB 580 billion unfulfilled order backlog.

• Oligonucleotide and peptide API TIDES manufacturing • Small molecule drug development and manufacturing • Cell and gene therapy CDMO services • Laboratory testing and preclinical services